RT Journal Article
SR Electronic
T1 Transient loss and recovery of oral chemesthesis, taste and smell with COVID-19: a small case-control series
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.27.23287763
DO 10.1101/2023.03.27.23287763
A1 Weir, Elisabeth M.
A1 Exten, Cara
A1 Gerkin, Richard C.
A1 Munger, Steven D.
A1 Hayes, John E.
YR 2023
UL http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287763.abstract
AB Anosmia is common with respiratory virus infections, but loss of taste or chemesthesis is rare. Reports of true taste loss with COVID-19 were viewed skeptically until confirmed by multiple studies. Nasal menthol thresholds are elevated in some with prior COVID-19 infections, but data on oral chemesthesis are lacking. Many patients recover quickly, but precise timing and synchrony of recovery are unclear. Here, we collected broad sensory measures over 28 days, recruiting adults (18-45 years) who were COVID-19 positive or recently exposed (close contacts per U.S. CDC criteria at the time of the study) in the first half of 2021. Participants received nose clips, red commercial jellybeans (Sour Cherry and Cinnamon), and scratch-n-sniff cards (ScentCheckPro). Among COVID-19 cases who entered the study on or before Day 10 of infection, Gaussian Process Regression showed odor identification and odor intensity (two distinct measures of function) each declined relative to controls (close contacts who never developed COVID-19), but effects were larger for intensity than identification. To assess changes during early onset, we identified four COVID-19 cases who enrolled on or prior to Day 1 of their illness – this allowed for visualization of baseline ratings, loss, and recovery of function over time. Four controls were matched for age, gender, and race. Variables included sourness and sweetness (Sour Cherry jellybeans), oral burn (Cinnamon jellybeans), mean orthonasal intensity of four odors (ScentCheckPro), and perceived nasal blockage. Data were plotted over 28 days, creating panel plots for the eight cases and controls. Controls exhibited stable ratings over time. By contrast, COVID-19 cases showed sharp deviations over time. No single pattern of taste loss or recovery was apparent, implying different taste qualities might recover at different rates. Oral burn was transiently reduced for some before recovering quickly, suggesting acute loss may be missed in data collected after acute illness ends. Changes in odor intensity or odor identification were not explained by nasal blockage. Collectively, intensive daily testing shows orthonasal smell, oral chemesthesis and taste were each altered by acute COVID-19 infection, and this disruption was dyssynchronous for different modalities, with variable loss and recovery rates across modalities and individuals.Competing Interest StatementDrs. Munger, Hayes, and Gerkin each hold equity in Redolynt, LLC, which they co-founded in 2021. This financial interest has been reviewed by the Individual Conflict of Interest Committee at each of their respective universities and is being actively being managed by each university. None of the other authors have any conflicts to disclose.Funding StatementEMW, SM, JEH and RCG each receive partial salary support from a competitive grant [1U01DC019573] from the National Institutes of Deafness and Communications Disorders (NIDCD); JEH also receives salary support from the United States Department of Agriculture (USDA) via the National Institute of Food and Agriculture (NIFA) Hatch Act Appropriations [Project PEN04708 and Accession # 1019852].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at The Pennsylvania State University gave ethical approval for this work (STUDY00016377).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study will be made available upon reasonable request to the authors.